Colitis pseudomembranosa enfoque anatomopatológico: A propósito de un caso: Pseudomembranosa colitis. anatomopathological approach: A purpose of a case

Pseudomembranous colitis is a serious digestive disease that develops in a context clinical-epidemiological quite predictable and most of the time, fatal. We present the case of a Elderly patient suffering left hip fracture, enters the hospital center and develops infection urinary, receiving broad-spectrum antibiotic therapy. Progressively, complications are installed respiratory, digestive and septic, being operated surgically to correct a clinical picture of intestinal obstruction, performing a sigmoidectomy. The macro and microscopic findings corresponded to a typical pseudomebranous colitis. The patient dies five days after the surgery. The entity is reviewed, with emphasis on the pathological findings, in order to make diagnoses safer and faster in future cases.   DOI 10.25176/RFMH.v18.n4.1739La Colitis pseudomembranosa es una enfermedad digestiva grave que se desarrolla en un contexto clínico-epidemiológico bastante predecible y la mayoría de las veces, fatal. Presentamos el caso de una paciente anciana que sufre fractura de cadera izquierda, ingresa al centro hospitalario y desarrolla infección urinaria, recibiendo terapia antibiótica de amplio espectro. Progresivamente, se instalan complicaciones respiratorias, digestivas y sépticas, siendo intervenida quirúrgicamente para corregir un cuadro clínico de obstrucción intestinal, realizándosele una sigmoidectomía. Los hallazgos macro y microscópicos correspondieron a una típica Colitis pseudomebranosa. La paciente fallece cinco días después de la cirugía. Se revisa la entidad, con énfasis en los hallazgos patológicos, a efectos de realizar diagnósticos más seguros y rápidos en casos futuros.   DOI 10.25176/RFMH.v18.n4.173

Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Summary Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung’s disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung’s disease) from 264 hospitals (89 in high-income countries, 166 in middleincome countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in lowincome countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. Interpretation Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between lowincome, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030

Em busca de um horizonte : narrativas sobre educação, artes e resistência

"APRESENTAÇÃO - Os textos reunidos no livro Em busca de um Horizonte: narrativas sobre educação, arte e resistência foram inspirados nos debates realizados durante o evento VI Simpósio Internacional Horizontes Humanos, que aconteceu na Faculdade de Educação da Universidade de Brasília, em 2018. O livro está dividido em quatro partes: Resistências cotidianas para além da utopia, Demasiado humano: as diferentes linguagens artísticas e culturais, A educação como um horizonte, Educação ambiental e ancestralidade: para continuar caminhando. Apesar da divisão em seções (sempre arbitrária), as produções - bastante diversas nas temáticas, metodologias e referenciais teóricos adotados – compartilham um alinhamento ao adotar um posicionamento político em defesa da diversidade, dos direitos humanos, da ancestralidade, do meio ambiente, da educação com valores democráticos, dos saberes populares e das diferentes linguagens artísticas. Assim, o livro se apresenta como um convite à resistência em tempos atrozes. Os organizadores

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. RESULTS: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m(2), and duration of T2DM was 9.3 ± 8.2 years. The qualifying ACS was a myocardial infarction in 83% and unstable angina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. CONCLUSION: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk